DCC (deleted in colorectal cancer), a candidate tumor suppressor gene located in chromosome band 18q21.2, encodes a transmembrane protein of 1447 amino acids. Neogenin, a protein with nearly 50% amino acid identity to DCC, was recently identi®ed because of its dynamic expression in the developing nervous system and gastrointestinal tract of the chicken. To explore a role for the human neogenin (NGN) gene in cancer, we have isolated cDNAs for two alternatively spliced forms of NGN, encoding proteins of 1461 and 1408 amino acids. Fluorescence in situ hybridization studies (FISH) localized NGN in chromosome band 15q22, a region infrequently aected by alterations in cancer. NGN transcripts of about 7.5 and 5.5 kb were detected in all adult tissues studied. In contrast to the frequent loss of DCC expression, no alterations in NGN expression were observed in more than 50 cancers studied, including glioblastoma, medulloblastoma, neuroblastoma, colorectal, breast, cervical and pancreatic cancer cell lines and xenografts. Based on their sequence conservation and similar expression during development, DCC and NGN may have related functions. However, the chromosomal location and ubiquitous expression of NGN in various human tumors suggest it is infrequently altered in cancer.
Introduction
Enormous progress has been made in describing genetic alterations in human cancer cells (Bishop, 1991; Knudson, 1993; Fearon, 1995) . The identification of more than 50 dierent oncogenes has been facilitated by the prior isolation of viral oncogenes, the detection and characterization of translocation breakpoints in cancer cells, and the ability of some oncogenes to promote tumorigenic growth when transferred to nontumorigenic recipient cells. Despite much recent attention, only about 15 tumor suppressor and candidate tumor suppressor genes have been molecularly cloned (Knudson, 1993; Fearon, 1995) . Results from several independent experimental approaches, however, suggest that a sizeable number of suppressor genes await discovery (Knudson, 1993; Fearon, 1995; Lasko et al., 1991; Vogelstein et al., 1989; Sato et al., 1990; Tsuchiya et al., 1992; Yamaguchi et al., 1992; Seymour et al., 1994; Hahn et al., 1995; Cliby et al., 1993; Fujino et al., 1994; AhSee et al., 1994; Knowles et al., 1994; Mitra et al., 1994) .
The existence of a tumor suppressor gene(s) on chromosome 18q was ®rst suggested by frequent allelic losses of 18q in colorectal cancers (Vogelstein et al., 1988 (Vogelstein et al., , 1989 . Subsequent studies identi®ed the DCC (deleted in colorectal cancer) gene at 18q21.2 as a candidate suppressor gene (Fearon et al., 1990) . DCC is an enormous gene spanning greater than 1.35 million base pairs (bp) , and it encodes a 1447 amino acid transmembrane protein with four immunoglobulin like and six ®bronectin type III like extracellular domains, a single membrane spanning region and a 325 amino acid cytoplasmic domain Reale et al., 1994) . Using sensitive assays, DCC transcripts have been detected in most adult tissues, with highest expression seen in the developing brain and neural tube (Fearon et al., 1990; Hedrick et al., 1994; Reale et al., 1994; Chuong et al., 1994; Pierceall et al., 1994; Cooper et al., 1995) .
DCC expression is reduced or absent in the majority of colorectal cancers, though speci®c somatic mutations in DCC have only been identi®ed in a subset of cases (Fearon et al., 1990; Cho et al., 1994; Cho and Fearon, 1995) . Loss of DCC expression has also been seen in cancers of the breast, pancreas, endometrium, prostate and brain, as well as male germ cell cancers, leukemias and neuroblastomas (Cho and Fearon, 1995; Reale et al., 1996) , suggesting that DCC inactivation may be an important factor in the development and/or progression of a variety of cancers besides those arising in the colon and rectum. A tumor suppressor function for DCC has, in fact, recently been demonstrated in a human squamous cancer cell line (Klingelhutz et al., 1995) .
A protein with roughly 50% amino acid identity to DCC, termed neogenin, was identi®ed because of its dynamic pattern of expression in the developing nervous system and gastrointestinal tract of the chicken (Vielmetter et al., 1994) . Speci®cally, neogenin was induced in neural cells immediately prior to cell cycle withdrawal and terminal dierentiation. To further our understanding of NGN and explore the possibility that alterations in neogenin might be present in cancers, we have cloned the human neogenin (NGN) gene. In contrast to DCC, based on its pattern of expression in cancer cells and its chromosomal location, NGN appears to be infrequently altered in cancer.
Results

Identi®cation of NGN, a DCC-related gene
Given the frequent loss of DCC expression in many types of cancer, we sought to determine if DCC-related genes were also inactivated in cancer. A human expression sequence tag (T07322) with over 85% nucleotide identity to chicken neogenin, a DCCrelated gene, was identi®ed in the GenBank database. Using this sequence as a hybridization probe, we isolated cDNA clones from a fetal brain library spanning 5297 bp and containing the entire human neogenin (NGN) open reading frame (Figure 1) . Two alternatively spliced forms of neogenin were previously identi®ed in the chicken, the isoforms dier by the presence or absence of a 159 bp sequence in the neogenin cytoplasmic domain. We identi®ed both alternatively spliced forms. NGN protein products of 1461 and 1408 amino acids were predicted from the sequences (Figure 1) .
The extracellular domain of human NGN displayed features common to members of the neural cell adhesion molecule (N-CAM) family, with four immunoglobulin like and six ®bronectin type III (FN III) like domains. Eight potential asparagine (N)-linked glycosylation sites (N-X-S/T) were identi®ed in the approximately 1100 amino acid extracellular region (Figure 1) . A single hydrophobic membrane-spanning sequence was found. In the long isoform of NGN, a cytoplasmic domain of 338 amino acids with 14 potential phosphorylation sites was observed ( Figure  1) . Three of the sites are lost in the alternatively spliced short NGN isoform. Overall, the predicted amino acid sequence of human NGN was 86% identical to the chicken neogenin sequence, with the greatest similarity seen in the FN III and cytoplasmic domains ( Table 1) . Comparison of human NGN and DCC revealed that the proteins had identical domain structure and roughly 50% identity at the amino acid level ( Table  1 ). The cytoplasmic sequences of NGN and DCC were less well-conserved, with only about 37% identity at the amino acid level. However, their cytoplasmic domains do not share extensive similarity with any other proteins in the database.
NGN proteins
To demonstrate that the NGN cDNAs encoded proteins, Western blot analysis was performed with lysates of Cos-1 cells that had been transiently transfected with expression constructs encoding the two alternatively spliced forms of NGN. To facilitate their detection, vesicular stomatitis virus glycoprotein (VSV-G) epitope tags were fused to the carboxytermini of each protein. Both cDNAs encoded proteins migrating at about 190 kDa, with the shorter NGN isoform migrating slightly more rapidly (Figure 2 ). Given the eight potential N-linked glycosylation sites in the NGN extracellular domain and the fact that the 1447 amino acid DCC protein migrates at roughly 175 ± 190 kDa Reale et al., 1994) , the apparent molecular masses were in good agreement with those predicted from the NGN sequences.
Chromosomal localization of NGN
Data from allelic loss studies of various cancers suggest that a number of chromosomal regions contain novel Fearon, 1995 and Lasko et al., 1991) . Usinḡ uorescence in situ hybridization, we observed speci®c hybridization of a human NGN P1 clone to all four 15q chromatids in 20 of 20 metaphase spreads analysed (example shown in Figure 3 ). In these 20 metaphases, there were no signals on any other chromosome. Localization of NGN to band 15q22 was based on the position of the¯uorescence signals relative to chromosome landmarks. In previous studies, allelic losses of 15q have been infrequently observed in cancer (Lasko et al., 1991; Vogelstein et al., 1989; Sato et al., 1990; Tsuchiya et al., 1992; Yamaguchi et al., 1992; Seymour et al., 1994; Hahn et al., 1995; Cliby et al., 1993; Fujino et al., 1994; Ah-See et al., 1994; Knowles et al., 1994; Mitra et al., 1994) . Though one recent study suggested that 15q allelic losses were common in metastatic cancers of the breast, colon and lung, the losses were restricted to proximal 15q and did not include the 15q22 region (Wick et al., 1996) . Hence, based on its location and the allelotype studies carried out thus far, NGN is not likely to be frequently aected by allelic losses in cancer.
NGN and DCC expression in normal and neoplastic tissues
Using Northern blot analysis, NGN transcripts of about 7.5 and 5.5 kb were detected in all normal adult tissues studied ( Figure 4a and data not shown). In + RNA in each lane were hybridized to NGN (a) or DCC (b) cDNA probes. Following hybridization to NGN or DCC, the blots were stripped and rehybridized with a b-actin cDNA probe. The lanes contain RNA from heart (Hrt), brain (Brn), placenta (Pla), lung (Lng), liver (Liv), skeletal muscle (Skm), kidney (Kid), pancreas (Pan), spleen (Spl), thymus (Thy), prostate (Pro), testis (Tst), ovary (Ova), small intestine (S Int), colon (Col) and peripheral blood cells (P Bld). The mobility (in kb) of molecular weight markers is indicated at the right previous studies, DCC transcripts have been detected in most normal adult tissues (Fearon et al., 1990; Reale et al., 1994) . However, their very reduced abundance has often necessitated very sensitive detection methods, such as reverse transcription polymerase chain reaction (RT ± PCR). Although previous studies have suggested that DCC transcripts were only detectable by Northern blot analysis in adult brain (Fearon et al., 1990; Cooper et al., 1995) , we were able to detect DCC transcripts of about 10 kb and/or 7 kb in many adult tissues studied (Figure 4b and data not shown). Of note, in testis, we also detected abundant levels of DCC transcripts of altered size (5.5 and 4.0 kb). These altered DCC transcripts have not been characterized in detail.
We carried out ribonuclease (RNase) protection studies to determine the relative abundance of NGN and DCC transcripts in cancers. In glioblastomas, NGN expression was detected in all specimens studied ( Figure 5 , Table 2 ), while DCC expression was not detected in upwards of 40% of the specimens (Table 2) , con®rming previous results (Ekstrand et al., 1995) . NGN expression was also detected in all seven medulloblastoma xenografts studied, but DCC expression was absent in two of the seven tumors (Table 1) . In additional RNase protection and RT ± PCR studies, NGN expression was detected in all other cancer lines studied, including neuroblastoma, breast, colorectal, pancreatic, and cervical cancers (Figures 5 and 6, Table  2 ). In contrast, DCC expression was not detectable in the majority of these lines ( Figure 6 and Table 2 ).
Discussion
Neogenin, a protein with roughly 50% amino acid identity to DCC was ®rst identi®ed because of its dynamic regulation in the developing nervous system and gastrointestinal tract of the chicken (Vielmetter et al., 1994) . To further explore the role of the DCC/ Neogenin family of proteins in cancer, we have cloned the human Neogenin (NGN) gene and localized it to chromosome 15q22. NGN encodes a 1461 amino acid protein, with similar structure to DCC and 50.2% amino acid identity. NGN transcripts were found to be expressed in all normal adult tissues studied. In addition, NGN transcripts were also detected in virtually all cancer tissues and cell lines studied, including many tumors in which DCC expression was not detected. Loss of DCC expression in cancers does not establish that DCC is a tumor suppressor gene. Nonetheless, the data are consistent with the possibility. Unfortunately, because of its very large size (i.e. 41.35 million bp), de®nitive examination of the DCC locus for alterations aecting its expression in cancer cells, such as somatic mutations or increased methylation of its regulatory sequences, has not been possible. In contrast to DCC, the chromosomal location and ubiquitous expression of NGN in cancer suggest that it is unlikely to be a suppressor gene. The ®ndings presented here also imply that, despite their extensive sequence similarity, the biologic functions of DCC and NGN in cell growth regulation and cancer may be distinct.
Recent studies of genes regulating cell migration and axon guidance in the developing nervous system have provided interesting new clues into DCC and NGN function. The C. elegans unc-40 gene encodes a transmembrane protein with identical domain structure to DCC and NGN and about 25% amino acid identity with each (Chan et al., 1995) . Though it may also have other functions, unc-40 is necessary for the appropriate circumferential migration of a subset of cells and axons in the developing nematode (Hedgecock et al., 1990) . unc-40 is believed to function in the same pathway as another gene termed unc-6 (Hedgecock et al Culotti, 1994) . unc-6 encodes a secreted protein bearing signi®cant similarity to the amino-terminal region of the B2 chain of laminin, an extracellular matrix protein (Ishii et al., 1992) and two vertebrate homologues of unc-6, termed netrin-1 and netrin-2 have recently been identi®ed Kennedy et al., 1994) . The netrin proteins were initially identi®ed and puri®ed because of their ability to promote the outgrowth of commissural axons, but they also appear to function as chemoattractants for commissural axons Kennedy and Tessier-Lavigne, 1995) . Given the predicted similarity of UNC-40 to DCC and NGN, the findings suggests that DCC and NGN may play important roles in mediating directional cell migration in the developing nervous system.
What role, if any, would DCC, NGN and the netrins be expected to play in other tissues? Moreover, how would loss of DCC function contribute to the altered phenotype of cancer cells, particularly if NGN function is retained in the cells? As shown above, DCC and NGN are both expressed at low levels in virtually all adult tissues. We have cloned the human netrin-1 gene and have found it expressed in all adult tissues surveyed (Meyerhardt et al., unpublished observations). In addition, netrin-1 transcripts can be detected in many human cancer cell lines, including those derived from colorectal tumors (Meyerhardt et al., unpublished observations). The eects of netrins on epithelial cells are poorly understood. However, it is tempting to propose that netrins may provide growth inhibitory or dierentiation cues to epithelial cells. Given the substantial dierences between the DCC and NGN cytoplasmic sequences, cancer cells that have lost DCC function may fail to respond appropriately to netrin signals, despite retaining NGN expression. Alternatively, DCC alterations may contribute to defects in the migratory properties of cancer cells or their failure to respect tissue boundaries. Indeed, such an eect might account for the apparently more aggressive and metastatic growth properties of some cancer cells lacking DCC expression (Cho and Fearon, 1995; Reale et al., 1996) .
Materials and methods
Cloning of NGN
A 312 basepair (bp) polymerase chain reaction (PCR) product corresponding to a human expression sequence tag (T07322) with 85% identity to chicken neogenin was ampli®ed from an oligo-dT primed human fetal brain library (Stratagene Cloning Systems, La Jolla, CA) using two oligos (5'-TTACGCCATTGGTTATG-3' and 5'-CAC-CATCAGGATTACGTG-3') derived from the ends of the sequence tag. The PCR product was labeled with [ 32 P]dCTP by random priming and used to screen the fetal brain library. Approximately 2610 6 plaques were lifted onto Hybond N + nylon ®lters (Amersham, Arlington Heights, IL). The ®lters were hybridized and washed as described (Vogelstein et al., 1987) . A total of 19 independent clones were isolated by multiple rounds of hybridization selection. Phagemids were rescued by in vivo excision with the ExAssist/SOLR system provided with the library.
DNA sequencing
Both strands of overlapping, double-stranded phagemid clones, containing the entire open reading frame of NGN (GenBank #U61262), were sequenced in their entirety using a combination of external and internal primers and exonuclease III/mung bean nuclease deletions (Stratagene). Plasmid DNA was prepared using Qiagen Spin Plasmid Kit (Qiagen, Inc., Chatsworth, CA) and sequenced by the dideoxy chain termination method using Sequenase 2.0 (U.S. Biomedical Corp., Cleveland, OH) and a modi®ed protocol (Kraft et al., 1988) . Sequencing reactions were electrophoresed on 6% polyacrylamide (19 : 1 acrylamide : bis-acrylamide)/8.0 M urea/16TBE gels. After drying, the gels were exposed to X-OMAT ®lm (Eastman Kodak, Rochester, NY).
NGN expression constructs
Full-length cDNAs encoding each of the two alternatively spliced forms of NGN were constructed from the overlapping fetal brain cDNAs. PCR was used to fuse a vesicular stomatitis virus glycoprotein (VSV-G) epitope tag (YTDIEMNRLGK) to the carboxyterminus of each of the two full-length NGN cDNAs. The modi®ed cDNAs were sequenced to verify that no errors had been introduced. The tagged cDNAs were subcloned into the pcDNA3 mammalian expression vector (Invitrogen Corp., San Diego, CA).
Western blot analysis
Transfections of Cos-1 cells (American Type Culture Collection [ATCC], Rockville, MD) were performed with Lipofectamine (Gibco BRL Life Technologies, Gaithersburg, MD) per the manufacturer's instructions. Protein extracts were prepared from the cells 48 h after transfection as previously described (Pierceall et al., 1994; Ekstrand et al., 1995) . Following electrophoresis on an 8% SDS-polyacrylamide gel and transfer to Immobilon-P membranes (Millipore, Bedford, MA) with a semidry electroblotter (Bio-Rad, Hercules, CA), tagged proteins were detected with a polyclonal rabbit anti-VSV-G antiserum (MBL International, Watertown, MA) and a donkey anti-rabbit IgG coupled to horseradish peroxidase (Pierce Biochemicals, Rockford, IL). Antibody complexes were detected by enhanced chemiluminescence (ECL) (Amersham, Arlington Heights, IL) and subsequent exposure to Kodak X-OMAT ®lm.
P1 clone isolation and¯uorescence in situ hybridization (FISH)
The p1 library (DMPC-HFF#10) was screened by Genome Systems, Inc. (St Louis, MO) with two NGN primers derived from sequences at the end of the coding region and the downstream 3' untranslated region (nucleotides 4465 ± 4645; sense oligo 5'-GAGATGGCC-CACCTGGAAGGAC-3' and antisense oligo 5'-GTCTGCTGGCTGATTCTG-TGTT-3'). Three P1 clones were isolated (DMFC-HFF#1-113-H12, -531-A11 and -1421-D6 (Franke, 1994) .
RNA isolation
Brain tumor xenografts were established from primary human glioblastomas and medulloblastomas and propagated in nude mice as previously described (Schold et al., 1983) . Pancreatic xenografts were established from pancreatic adenocarcinomas (Hahn et al., 1995) . Human neuroblastoma cell lines SJNB-7, -8, -10, -11 and -17 were derived from advanced stage primary tumors at St. Jude Children's Research Hospital. All other cell lines were purchased from ATCC. Total RNA was isolated from minced brain tumor xenograft tissues or pelleted tumor cells, using Trizol reagent (Gibco BRL Life Technologies) or the RNAgents RNA isolation system (Promega, Madison, WI).
Northern analysis
Northern blots of normal human adult tissues (approximately 2 mg of poly(A) + RNA loaded per lane) were purchased from ClonTech (ClonTech Laboratories, Inc., Palo Alto, CA). Hybridization were performed according to the manufacturer's instructions using a 486 bp 32 Plabeled NGN cDNA probe (corresponding to amino acids 330 ± 491) or a 4.35 kb 32 P-labeled DCC cDNA probe . Following hybridization, blots were washed with 26 SSC/0.5% SDS for 45 min at room temperature, with a subsequent increased stringency wash of 0.16SSC/0.1% SDS for 30 min at 508C. Blots were stripped per the manufacturer's instructions, and reprobed with a 32 P-labeled 2.0 kb cDNA fragment of b-actin, provided by ClonTech.
Ribonuclease protection assay
Ribonuclease (RNase) protection assays were performed essentially as described (Pierceall et al., 1994; Ekstrand et al., 1995) . A NGN riboprobe was generated from pAMP1-T07322, a plasmid containing a 312 bp NGN cDNA fragment (corresponding to amino acids 771 ± 873). The DCC riboprobe has been previously described (Ekstrand et al., 1995) . To control for loading, g-actin and b-actin riboprobes were used. The g-actin riboprobe has been described (Ekstrand et al., 1995) , and the b-actin riboprobe was prepared from the pTRI-b-actin-125-human plasmid construct (Ambion, Inc., Austin, TX). Probes were labeled with [
32 P]CTP, and following puri®cation through an acrylamide gel, 1.0610 6 c.p.m. of the NGN and 2.0610 5 c.p.m. of the g-actin or b-actin riboprobe were incubated with 10 mg of RNA. Similarly, 1.0610 6 c.p.m. of the DCC riboprobe and 2.0610 5 c.p.m. of the g-actin riboprobe were hybridized overnight with 20 mg of RNA. Non-hybridizing sequences were digested with RNase T2 (Gibco BRL Life Technologies). Protected fragments were recovered by ethanol precipitation and electrophoresed on a denaturing polyacrylamide sequencing gel. After drying the gel, autoradiography was carried out with X-OMAT ®lm and intensifying screens.
RT ± PCR assay
Total RNA was treated with two units of RNase-free DNase (Boehringer Mannheim). First-strand cDNA was prepared from three micrograms of RNA using AMV reverse transcriptase (Promega) and random hexamers. One tenth of the cDNA was used for each PCR with primer pairs derived from the human DCC and NGN sequences. Extracellular domain NGN primers (corresponding to amino acids 329 ± 491) were NGN329S-5'-TTGAAGCTCAAGCAGAGCTTACAG-3' and NGN-491A-5'-GACTGGTATTCTCAACACGTTCC-3'. NGN cytoplasmic domain primers (amino acids 1128 ± 1239) were NGN1128S-5'-GTACCCGTCGTACCACCTCTCA-CC-3' and NGN1239A-5'-CATCATTTTTGGTCTCATT-CCTCG-3'. DCC extracellular domain primers (amino acids 93 ± 221) were DCC902S-5'-CAAATGGGTCTCT-GCTGATAC-3' and DCCEX3A-5'-TCTTGAGCTGGC-TGGATTTCGAGC-3'. DCC cytoplasmic domain primers (amino acids 1110 ± 1309) were DCK3090S-5'-CACAGT-GCTGGTAGTGGTCAT-3' and DCK4504A-5'-TTGGG-TTGATGGTCCTTCACTCAC-3'.
Ampli®cations were performed using the following conditions: hotstart followed by 35 cycles of 948C645 s, 558C645 s and 728C62.5 min. One-®fth of each reaction was electrophoresed on 1.2% agarose gels and visualized with u.v. light following ethidium bromide staining. The identities of the DCC and NGN products were con®rmed by Southern transfer and hybridization with their respective 32 P-labeled cDNA probes. A set of b-actin primers was used to independently con®rm the ®rst strand cDNA reaction. For all samples studied, the results with the two sets of NGN primers were concordant. Similarly, concordant results were obtained with the two sets of DCC primers.
Abbreviations DCC -deleted in colorectal cancer; NGN -human neogenin; FN III -®bronectin type III, Ig -immunoglobulin; bp -base pair; kb -kilobase pair; RNase -ribonuclease; RT ± PCR -reverse transcription polymerase chain reaction; VSV-G -vesicular stomatitis virus glycoprotein; kDakilodalton; ECL -enhanced chemiluminescence.
